PLAY PODCASTS
Stocks and Crypto Extend Slump, Exclusive With Take-Two CEO on Zynga Deal, and Gilead Sciences CEO on the Battle to Treat COVID

Stocks and Crypto Extend Slump, Exclusive With Take-Two CEO on Zynga Deal, and Gilead Sciences CEO on the Battle to Treat COVID

Carl Quintanilla, Jim Cramer and David Faber explored how investors should navigate a rough start to the week for stocks: The tech sector extending its 2022 sell-off amid rising bond yields. Bitcoin and other cryptocurrencies also continuing to take a hit. Take-Two Interactive was the S&P 500's worst performer after the home of "Grand Theft Auto" announced it has agreed to acquire mobile gaming company Zynga for $9.86 per share in cash and stock, representing a 64% premium to Friday's closing price. Take-Two Chairman & CEO Strauss Zelnick appeared on the program exclusively to discuss the deal. As part of CNBC's coverage of the virtual J.P. Morgan Health Care Conference, Meg Tirrell interviewed Gilead Sciences CEO Daniel O'Day about his company's antiviral "Remdesivir" and how the treatment is faring against the COVID-19 omicron variant. Carl, Jim and David reacted to Wall Street firms' top stock picks for 2022.

Squawk on the Street

January 10, 202242m 58s

Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

Carl Quintanilla, Jim Cramer and David Faber explored how investors should navigate a rough start to the week for stocks: The tech sector extending its 2022 sell-off amid rising bond yields. Bitcoin and other cryptocurrencies also continuing to take a hit. Take-Two Interactive was the S&P 500's worst performer after the home of "Grand Theft Auto" announced it has agreed to acquire mobile gaming company Zynga for $9.86 per share in cash and stock, representing a 64% premium to Friday's closing price. Take-Two Chairman & CEO Strauss Zelnick appeared on the program exclusively to discuss the deal. As part of CNBC's coverage of the virtual J.P. Morgan Health Care Conference, Meg Tirrell interviewed Gilead Sciences CEO Daniel O'Day about his company's antiviral "Remdesivir" and how the treatment is faring against the COVID-19 omicron variant. Carl, Jim and David reacted to Wall Street firms' top stock picks for 2022. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.